Lyndra Therapeutics appoints Jenkins, Fernandes to executive roles

Lyndra Therapeutics announced today that it appointed Abigail Jenkins and Jacqueline Fernandes to executive positions […]

Lyndra Therapeutics announced today that it appointed Abigail Jenkins and Jacqueline Fernandes to executive positions at the company.

Jenkins will take over as chief commercial & business officer, while Fernandes assumes the role of VP of data compliance and information technology at the Watertown, Mass.-based developer of oral, long-acting, sustained-release therapeutics.

“We are pleased to be expanding Lyndra’s executive team with the appointment of two experienced and accomplished industry executives. Both women fill key positions at Lyndra as we continue to grow and position ourselves for the approval of five products by 2025,” Lyndra CEO Dr. Patricia Hurter said in a news release. “Abigail’s reputation for combining science, strategic planning and vision to build and lead successful commercial healthcare operations will be invaluable to the Company as Lyndra advances from the clinical to commercial stage with the initiation of our first pivotal trial of LYN-005 as a once-weekly oral treatment for schizophrenia later this year.

“Likewise, Jacqueline’s decades of experience creating strategic IT frameworks to ensure compliance, security and scalability across growing organizations will enable rapid and streamlined development across all aspects of the business.”

Jenkins, a veteran of more than 20 years on the commercial and business side of life science, most recently served as senior VP & business unit head of vaccines at Emergent BioSolutions. She’s also held roles at Aquinox Pharmaceuticals, Relypsa, Actavis, MedImmune and Pfizer.

“I’m very excited to work alongside this passionate and driven team of healthcare pioneers working to fundamentally change the way people around the world take medicine,” Jenkins said. “I look forward to building the foundation for successful commercialization of Lyndra’s robust pipeline as well as forging innovative industry partnerships as the Company prepares for its next stage of corporate growth.”

Fernandes also has two decades of experience in her field as far as designing and implementing data and IT compliance programs across several types of organizations. She previously served as senior director of data compliance and chief privacy officer at Sarepta Therapeutics. She has also held senior-level roles at Sunovion Pharmaceuticals, the state of Massachusetts, the Dept. of Transportation, Intel and Comcast.

Jacqueline Fernandes, Vice President of Data Compliance and Information Technology

“Lyndra is poised for significant near- and long-term growth and transformation as the Company continues to advance its novel ultra-long-acting oral therapies,” Fernandes said. “I’m eager to contribute to this meaningful work by ensuring and enabling safe and compliant procedures that protect the business and its stakeholders.”

Original Article: (